
Jing Liang 🇺🇦
35.3K posts

Jing Liang 🇺🇦
@AppleHelix
Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: https://t.co/yDWRnOYAyY https://t.co/SOf8c5OZm6




According to ⬇️, some FDA political appointees have financial ties to the Arnold family foundation/ventures. There's documentation of this elsewhere so it's not only an anonymous X acct saying this. $ from ideological group that's against HIV & hep C drugs too $XBI $BBC $IBB




Congrats to Erica Scheller, PhD, DDS @WashUMedBMD on recent publication in Nature Metabolism. Researchers from Scheller Lab identified a potent pathway that begins in the brain and leads to loss of all body fat without reducing food intake. Learn more > internalmedicine.wustl.edu/specific-brain…

$LLY In the phase 2 Retatrutide trial 19% cardiac arrhythmias- need to see that safety in this phase 3 trial ???




Okay, Before today, I knew Arnold Ventures funded Vinay Prasad - but I didn't know the amount. Today I learned that: - Vinay Prasad was funded by ~$4m grants from 2017-23, and continues to be funded by AV - Marty Makary was also funded by AV - $500-$1m in grants - Tracy Beth Hoeg was supported indirectly by Arnold Ventures while working in Vinay Prasad's lab So basically Arnold Ventures was able to place ideologically aligned people at the FDA. TO BE CLEAR, I think @Arnold_Ventures does great things. I agree with its goal of lowering cost of medicines. However, I disagree with its approach. I also think sometimes, they end up funding ideologues - people who wants to "prove" their biases rather than being evidence or fact-driven.






@canoebrookbl @masterlongevity Arnold Ventures is not the typical NGO, so I would suggest explicit corruption is very unlikely. However it is likely that they all have related ideologies.




Let's look at how the FDA is treating $SRPT and $QURE differently. The FDA grants accelerated approval to Amondys and Vyondys to treat Duchenne muscular dystrophy. Sarepta conducts a post-marketing confirmatory study that fails to show a benefit for either drug. There is no evidence that patients are benefiting from either drug, based the outcome of a randomized, controlled study. Still, Sarepta pushes forward, seeking to convert accelerated approval to final approval. The FDA allows Sarepta to submit an application. "The adequacy of the data to support conversion to traditional approval will be a matter of review," the FDA concludes, according to Sarepta. Amondys and Vyondys should be withdrawn from the market. My opinion. I've said that repeatedly. There's a process, of course, so FDA should review the data. That's what regulators are supposed to do. And then, there's UniQure and AMT-130, its treatment for Huntington's disease.... The FDA won't even allow UniQure to submit an application for accelerated approval. Bar the door, the FDA says, not even a review. investorrelations.sarepta.com/news-releases/…





The 340B program was designed to help rural and underserved areas, but @CMSGov estimates just seven percent of Medicaid hospital spending even reaches rural hospitals. @RepBuddyCarter wants answers on how we can make the 340B program actually work for those it was made for. ⬇️ WATCH ⬇️

